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Abstract: 11C-methionine (11C-MET) is a new positron emission tomography (PET) tracer for the
assessment of disease activity in multiple myeloma (MM) patients, with preliminary data suggesting
higher sensitivity and specificity than 18F-fluorodeoxyglucose (18F-FDG). However, the value of tumor
burden biomarkers has yet to be investigated. Our goals were to corroborate the superiority of 11C-MET
for MM staging and to compare its suitability for the assessment of metabolic tumor burden biomarkers
in comparison to 18F-FDG. Twenty-two patients with newly diagnosed, treatment-naïve symptomatic
MM who had undergone 11C-MET and 18F-FDG PET/CT were evaluated. Standardized uptake
values (SUV) were determined and compared with total metabolic tumor volume (TMTV) for both
tracers: total lesion glycolysis (TLG) and total lesion 11C-MET uptake (TLMU). PET-derived values
were compared to Revised International Staging System (R-ISS), cytogenetic, and serologic MM
markers such as M component, beta 2 microglobulin (B2M), serum free light chains (FLC), albumin,
and lactate dehydrogenase (LDH). In 11 patients (50%), 11C-MET detected more focal lesions (FL) than
FDG (p < 0.01). SUVmax, SUVmean, SUVpeak, TMTV, and TLMU were also significantly higher in
11C-MET than in 18F-FDG (p < 0.05, respectively). 11C-MET PET biomarkers had a better correlation
with tumor burden (bone marrow plasma cell infiltration, M component; p < 0.05 versus p = n.s.
respectively). This pilot study suggests that 11C-MET PET/CT is a more sensitive marker for the
assessment of myeloma tumor burden than 18F-FDG. Its implications for prognosis evaluation need
further investigation.
Keywords: multiple myeloma; methionine; total lesion glycolysis (TLG); metabolic tumor volume
(MTV); total lesion methionine uptake (TLMU)
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1. Introduction
Multiple myeloma (MM) is a malignant disorder of clonal plasma cells (PCs) that represents
approximately 10% of hematological malignancies [1]. Positron emission tomography (PET)
in combination with computed tomography (CT) and 18F-fluorodeoxyglucose (18F-FDG) is a
well-established imaging technique in MM. It has proven its value in the assessment of tumor
burden and disease activity in MM, with sensitivity and specificity ranging from 80% to 100% [2,3].
Additionally, it has demonstrated prognostic impact, and the presence of more than three focal lesions
(FL), maximum standardized uptake values (SUVmax) higher than 4.2, or the presence of extramedullary
disease are, indeed, predictors of poor prognosis [4,5]. On top of this, post-therapy imaging studies
have demonstrated that PET negativity after induction treatment [6,7] or autologous/allogeneic stem
cell transplantation (ASCT) [7–10] correlates with longer progression-free survival (PFS). Moreover,
new parameters measuring tumor burden in 18F-FDG PET/CT such as metabolic tumor volume
(MTV) and total lesion glycolysis (TLG) have also demonstrated an association with survival in
MM patients [11,12]. Furthermore, patients with high TLG had poor outcome even in the context
of molecularly defined low-risk disease, highlighting the additional value of novel markers in the
assessment of MM.
Nevertheless, 18F-FDG PET/CT is associated with several shortcomings: (1) the sensitivity is poor
in patients with diffuse bone marrow (BM) infiltration; (2) 18F-FDG avidity may be absent in patients
with low hexokinase-2 expression [13] and specificity is not reliable in inflammatory or infectious
lesions. For these reasons, alternative tracers such as 11C-methionine (11C-MET) [14], 11C-choline [15],
or radiolabeled C-X-C chemokine receptor 4 ligands [16,17] have been investigated. Several studies
have suggested a higher sensitivity of 11C-MET PET/CT over 18F-FDG PET/CT in the detection of both
intra- and extramedullary disease [18,19]. In addition, a better correlation of 11C-MET uptake with the
degree of BM infiltration by malignant PCs has been recently reported [20].
The aim of the study was to assess the diagnostic value of volume-based 11C-MET PET/CT
biomarkers in newly diagnosed, treatment-naïve MM patients in comparison to 18F-FDG.
2. Results
2.1. Patient-Based Analysis
On a patient basis analysis, both techniques were positive in all patients. In 11C-MET PET/CT,
diffuse BM infiltration, as a single abnormality, was detected in 6/22 (27.3%) patients, while FL only
were present in 3/22 cases (13.6%), and a combined pattern (both focal and diffuse) was detected in
13/22 patients (59.1%). With 18F-FDG PET/CT, disease was categorized as only diffuse BM in 6/22
(27.3%), FL in 10/22 (45.5%), and a combined pattern in 6/22 (27.3%) patients. These results indicate
that 11C-MET PET/CT was able to detect combined infiltration in more patients than 18F-FDG PET/CT
(13 versus 6 cases, respectively) (Figure 1), while 18F-FDG detected FL in more patients than 11C-MET
(p = 0.003). No extramedullary disease was identified. An incidental finding consisting of a focal
uptake on the right lobe of the prostate was only detected by 18F-FDG PET/CT and turned out to be an
adenocarcinoma (Figure 1).
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Figure 1. Display of a 68-year-old male with Bence–Jones kappa multiple myeloma Revised 
International Staging System (R-ISS) II. In 18F-fluorodeoxyglucose (18F-FDG) positron emission 
tomography (PET)/computed tomography (CT), focal lesions (FL) located on the right thyroid 
cartilage and sacral bone were identified. Nevertheless, the focal uptake on the lower cervical region 
and left clavicle corresponded to a lymph node and a fracture, respectively, and were thus 
considered unspecific findings. Please note that diffuse uptake in 18F-FDG PET/CT was 
homogeneous and below the liver cut-off. Conversely, a combined infiltration pattern with bone 
marrow (BM) infiltration and more than 10 FL was present in 11C-MET PET/CT. Importantly, they 
did not demonstrate a correlation in 18F-FDG PET/CT (fusion images). 
2.2. Lesion-Based Analysis 
On a lesion basis analysis, 18F-FDG and 11C-MET were concordant, depicting > 3 FL in seven 
patients, < 3 FL in five patients, and diffuse infiltration in five patients (kappa agreement index = 
0.66) (Table 1). However, more FL were detected by 11C-MET in 11 patients (50%, p < 0.01), 3 patients 
with FL, and 8 patients with combined infiltration (Figure 2). By contrast, 18F-FDG detected more FL 
in only one patient. 
Table 1. Comparison of diagnostic performance for 18F-FDG and 11C-methionine (11C-MET) PET/CT. 
PET/CT results 
MET-PET 
Total Focal, > 3 FL Combined, < 3 FL Combined, > 3 FL Diffuse 
FDG-PET Focal, < 3 FL 0 1 3 0 4 
Focal, > 3 FL 3 0 3 0 6 
Combined, < 3 FL 0 4 0 1 5 
Combined, > 3 FL 0 0 1 0 1 
Diffuse 0 1 0 5 6 
Total 3 6 7 6 22 
i 1. Display of a 68-year old ma e with Bence–Jon s kappa multi le myeloma Revis d International
Stagi g System (R-ISS) II. In 18F-fluorodeoxygluc se (18F-FDG) positron emission tomography
(PET)/computed tomography (CT), focal lesions (FL) located on the right thyroid cartilage an
s cral bone were identifi d. N vertheless, the focal uptake on the lower c rvical region and left clavicle
corresponded to a lymph ode and a fracture, respectively, and were thus considered unspecific
findings. Please note that diffuse uptake in 18F-FDG PET/CT was homoge eous and below the liver
cut-off. Conversely, a combin d infiltration pattern with bone marrow (BM) infiltration and more than
10 FL as prese t in 11C-MET PET/CT. Importantly, they did not demonstrate a correlation in 18F-FDG
PET/CT (fusi images).
2.2. Lesion-Based Analysis
On a lesion basis analysis, 18F-FDG and 11C-MET were concordant, depicting > 3 FL in seven
patients, < 3 FL in five patients, and diffuse infiltration in five patients (kappa agreement index = 0.66)
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FL, and 8 patients with combined infiltration (Figure 2). By contrast, 18F-FDG detected more FL in only
one patient.
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Figure 2. Display of a 47-year-old male (patient #10) with multiple myeloma R-ISS II. A combined 
pattern of diffuse and focal disease and more than three FL were detected by 18F-FDG PET/CT. The 
same lesions were detected by 11C-MET PET/CT and, noticeably more FL were detected, some of 
them located in the skull, leading to a remarkable difference of 103.3% in total metabolic tumor 
volume (TMTV) (TMTV MET: 726 cm3 vs. TMTV FDG: 357.1) and 366.1% in TLG/TLMU (MET 
TLMU: 6061.4 g vs. FDG TLG: 1300.4 g). 
2.3. PET-Derived Biomarkers 
We analyzed SUVmax, SUVmean, and SUVpeak for both techniques. Median, inter-quartile 
range (IQR), and SUVmax values were significantly higher for 11C-MET (16.40 (6–195.6)) than for 
18F-FDG PET/CT (8.76 (3.45–62.23)) (p = 0.008). The same difference was observed for median 
SUVmean (11C-MET: 4.59 (2.79–8.35) versus 18F-FDG: 3.55 (1.82–7.74), p = 0.022 and SUVpeak 
(11C-MET: 10.72 (4.64–126.50) versus 18F-FDG: 6.56 (2.82–39.85), p = 0.005.  
Regarding volume-based biomarkers, median total metabolic tumor volume (TMTV) for 
11C-MET PET/CT (443.4 cm3 (145.2–1102.6)) was significantly higher than median TMTV for 18F-FDG 
(134.8 cm3 (5.6–524.9); p < 0.001) with a median difference of 141.2% (21.6–18,369). The same finding 
was observed for total lesion 11C-MET uptake (TLMU) (11C-MET, median: 2021.4 g (761.6–6061.4) 
versus TLG 18F-FDG, median: 598.4 g, (10.7–2086.4), p < 0.001) with a median difference of 216.7% 
(40.3–19,212.2). 
Global comparisons of TMTV and TLG/TLMU between 11C-MET and 18F-FDG PET/CT, as well 
as differences for each tracer depending on uptake patterns are shown in Figure 3. Differences in 
TMTV and TLG/TLMU between the two tracers on a patient’s based analysis are shown in Figure 4. 
Figure 2. Display of a 47-year-old male (patient #10) with multiple myeloma R-ISS II. A combined
pattern of diffuse and focal disease and more than three FL were detected by 18F-FDG PET/CT. The same
lesions were detected by 11C-MET PET/CT and, noticeably more FL were detected, some of them
located in the skull, leading to a remarkable difference of 103.3% in total metabolic tumor volume
(TMTV) (TMTV MET: 726 cm3 vs. TMTV FDG: 357.1) and 366.1% in TLG/TLMU (MET TLMU: 6061.4 g
vs. FDG TLG: 1300.4 g).
2.3. PET-Derived Biomarkers
We analyzed SUVmax, SUVmean, and SUVpeak for both techniques. Median, inter-quartile
range (IQR), and SUVmax values were significantly higher for 11C-MET (16.40 (6–195.6)) than for
18F-FDG PET/CT (8.76 (3.45–62.23)) (p = 0.008). The same difference was observed for median SUVmean
(11C-MET: 4.59 (2.79–8.35) versus 18F-FDG: 3.55 (1.82–7.74), p = 0.022 and SUVpeak (11C-MET: 10.72
(4.64–126.50) versus 18F-FDG: 6.56 (2.82–39.85), p = 0.005.
Regarding volume-based biomarkers, median total metabolic tumor volume (TMTV) for 11C-MET
PET/CT (443.4 cm3 (145.2–1102.6)) was significantly higher than median TMTV for 18F-FDG (134.8 cm3
(5.6–524.9); p < 0.001) with a median difference of 141.2% (21.6–18,369). The same finding was observed
for total lesion 11C-MET uptake (TLMU) (11C-MET, median: 2021.4 g (761.6–6061.4) versus TLG
18F-FDG, median: 598.4 g, (10.7–2086.4), p < 0.001) with a median difference of 216.7% (40.3–19,212.2).
Global comparisons of TMTV and TLG/TLMU between 11C-MET and 18F-FDG PET/CT, as well as
differences for each tracer depending on uptake patterns are shown in Figure 3. Differences in TMTV
and TLG/TLMU between the two tracers on a patient’s based analysis are shown in Figure 4.
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Figure 3. Global comparison of TMTV and total lesion glycolysis (TLG)/total lesion 11C-MET uptake 
(TLMU) between 11C-MET and 18F-FDG PET/CT scan (a), and comparison of TMTV and TLG/TLMU, 
according to the observed pattern, for 18F-FDG (b) and 11C-MET (c). 
 
Figure 4. Differences in TMTV (a) and TLG/TLMU (b) between the two tracers on a patient-based 
analysis sorted by tumor burden in 18F-FDG PET/CT. 
2.4. Correlation of PET Biomarkers with Tumor-Burden derived Parameters 
We have analyzed the correlations between four different PET parameters (presence of FL, 
SUVmax, SUVmean, and volumetric parameters: TMTV and TLG/TLMU) and different clinical 
variables that reflect myeloma burden (M-component, percentage of plasma cells (PC), beta 2 
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Figure 4. Differences in TMTV (a) and TLG/TLMU (b) between the two tracers on a patient-based
analysis sorted by tumor burden in 18F-FDG PET/CT.
2.4. Correlation of PET Biomarkers with Tumor-Burden derived Parameters
We have analyzed the correlations between four different PET parameters (presence of FL, SUVmax,
SUVmean, and vo umetric parameters: TMTV and TLG/TLMU) and different clinical variables that
reflect myelom burden (M-component, percen age of plasma cells (PC), beta 2 microglobulin (B2M),
free light chains (FLC) lev ls, creatinin , albumin, and Revis d I ernational Staging System (R-ISS).
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No correlation was found between the number of FL detected by 18F-FDG or 11C-MET PET/CT
and the M component (p = 0.71 for 18F-FDG PET and p = 0.81 for 11C-MET PET), B2M (p = 0.38 for
18F-FDG PET and p = 0.17 for 11C-MET PET), FLC levels (p = 0.24 for 18F-FDG PET and p = 0.82 for
11C-MET PET) nor R-ISS (p = 0.35 for 18F-FDG PET and p = 0.76 for 11C-MET PET).
Upon analyzing semi-quantitative parameters (SUVmax and SUVmean) obtained by 18F-FDG
PET/CT, a moderate correlation was found with both SUVmax and SUVmean and high β2M levels
(>3.5 mg/L) (SUVmax: rs = –0.458, p = 0.03; SUVmean: rs = –0.417; p = 0.05). However, no significant
correlation was detected between SUVmean and SUVmax in 18F-FDG and albumin < 3.5 g/dL (p = 0.12
for SUVmax and p = 0.19 for SUVmean) or creatinine > 2 mg/dL (p = 0.66 for SUVmax, p = 0.44 for
SUVmean).
In 11C-MET PET/CT, no correlation was identified between SUVmax and SUVmean and
albumin < 3.5 g/dL (p = 0.38 for SUVmax and p = 0.43 for SUVmean), creatinine > 2 mg/dL (p = 0.74 for
SUVmax, p = 0.44 for SUVmean), or β2M > 3.5 mg/L (p = 0.29 for SUVmax and p = 0.64 for SUVmean).
In addition, no differences were present between SUVmax values and cytogenetic risk in 18F-FDG
PET/CT nor 11C-MET PET/CT (p = 0.32 for 18F-FDG and p = 0.66 for 11C-MET).
Finally, we explored correlations between volumetric parameters (TMTV and TLG/TLMU values)
obtained with both tracers and clinical variables. A positive correlation was found between TMTV and
B2M levels both in 18F-FDG PET/CT (r = 0.434, p = 0.044) and in 11C-MET PET/CT (r = 0.569, p = 0.006),
in which the latter had a higher correlation. Moreover, in 11C-MET PET/CT, significant correlations
between TMTV and the M-component (r = 0.781, p = 0.003) or BM infiltration (0.571, p = 0.007) were
recorded. With respect to TLG, no correlations were detected in 18F-FDG PET/CT, whereas moderate to
good positive correlations were demonstrated in 11C-MET PET/CT for TLMU and B2M levels (r = 0.428,
p = 0.047), TLMU, M component (r = 0.616, p = 0.033), and TLMU and BM infiltration (r = 0.450,
p = 0.041). No other correlations were present for the rest of the serum parameters explored.
3. Discussion
The use of PET-CT has rapidly expanded in MM both for the evaluation of disease extension at
presentation (particularly for detection of extramedullary disease) as well as for treatment response
assessment [21]. Although 18F-FDG is the gold standard radiotracer, recent data suggest that 11C-MET
may be a potentially superior radiotracer for MM imaging due to higher sensitivity than 18F-FDG [22].
The current study conducted in patients with newly diagnosed, treatment-naïve MM confirms
the higher sensitivity of 11C-MET PET/CT, with about 50% of subjects demonstrating more lesions as
compared to 18F-FDG PET/CT, thus being in line with previous preliminary observations [18–20,22].
Furthermore, we have investigated for the first time 11C-MET PET volume-based biomarkers (TMTV,
TMLU) demonstrating a positive correlation with MM serum markers of tumor burden such as M
component, bone marrow (BM) infiltration, or B2M. In contrast, 18F-FDG derived markers only showed
a modest correlation with ß2M, while no association was found with other indicators of disease
including albumin, FLC, M component, or the percentage of BM infiltration by malignant plasma cells
(assessed by random iliac crest BM biopsy). Thus, 11C-MET might be considered a highly sensitive
radiotracer to be used as a non-invasive surrogate for the investigation of MM disease activity, including
the detection of minimal residual disease.
On the other hand, 18F-FDG PET/CT remains the standard technique for the nuclear medicine-based
evaluation of myeloma, given its availability and the vast body of experience in various clinical settings.
Beyond mere diagnostic accuracy, 18F-FDG has proven its prognostic value in various studies and
has even outperformed magnetic resonance imaging in terms of therapy monitoring and response
assessment [7]. In addition, recent studies with 18F-FDG PET/CT have investigated the prognostic value
of the new metabolic biomarkers (TMTV and TLG) and have suggested significant survival implications
at baseline and a more precise quantitation of the glycolytic phenotype of active disease [11,12]. The aim
of the current study was just to compare the performance of C-MET versus F-FDG in newly diagnosed
MM patients, and it was out of the scope to explore the prognostic value of C-MET due to the small
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sample size, retrospective nature, short follow up, and treatment heterogeneity. However, as mentioned
above, it is important to underscore the correlation between volume-based biomarkers and MM tumor
burden markers (both median TMTV and TLMU), which were clearly higher in 11C-MET PET/CT as
compared to 18F-FDG PET/CT. Whether this would translate in better survival prognostication and
individually tailored treatment decisions remains to be investigated. It is necessary to take into account
that the short half-life of C-11 makes necessary an on-site cyclotron, which could be a major limitation
for the tracer’s widespread use.
In addition, there is still a need for the standardization of segmentation methods when calculating
TMTV. In the present study, it was decided to segment individually by an absolute or a relative
threshold instead of employing a global threshold of the CT image, as described by Takahashi et al. [23]
or a fixed threshold of 40% of SUVmax as described by Fonti et al. [24]. In our experience, the use of a
fixed cut-off value does not necessarily work for all patients, especially when focal disease is present or
double tracer studies are carried out (Figure S1). Our proposal is to use a relative SUVmax threshold
(i.e., SUV > 41% of SUVmax) whenever diffuse or combined uptake is present, while in the presence
of FL only, results are not unequivocal and further studies are needed to achieve a general optimal
single threshold.
Despite all limitations mentioned above, this two-center study is the first that has investigated
11C-MET PET volume-based biomarkers (TMTV, TLMU) and demonstrated a correlation between
these new 11C-MET-PET biomarkers and other MM prognostic factors [14].
4. Materials and Methods
4.1. Study Description and Patient Population
The study has been approved by the University Hospital of Würzburg (212/13) and by the
University Clinic of Navarra (161/2015) ethics committees. All patients signed an informed consent
form according to the Declaration of Helsinki. 11C-MET was administered under the conditions of the
German and Spanish pharmaceutical law (German Medicinal Products Act, AMG §13 2b; RD 1015/2009)
and in accordance with the responsible regulatory bodies (Regierung von Oberfranken, Germany;
AEMPS, Spain).
Twenty-two consecutive patients with newly diagnosed, treatment-naïve MM referred for dual
tracer (18F-FDG and 11C-MET) staging PET/CT were retrospectively reviewed by PET experts from
the University Hospital of Würzburg (C.L., Würzburg, Germany) and University Clinic of Navarra
(M.J.G.-V., Pamplona, Spain). None of the patients have been previously reported in previous
publications. Patients with plasma cell malignancies other than MM (e.g., smoldering myeloma) were
excluded from the analysis. The following characteristics were documented and subsequently analyzed:
age, gender, hemoglobin, calcium, serum creatinine, C-reactive protein, B2M, albumin, M component,
percentage of malignant plasma cell infiltration as assessed by random bone marrow biopsy of the iliac
crest, lactate dehydrogenase (LDH), platelet count, type of monoclonal component, presence and level
of serum light chains, clinical staging according to the R-ISS, and chromosomal abnormalities defining
high-risk patients: t(4;14) and /or t(14;16) and/or del(17p). Patients´ characteristics are summarized in
Tables 2 and S1.
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Table 2. Patients’ characteristics.
No. Sex Age Myeloma Type R-ISS High-Risk Cytogenetics
1 male 75 IgG kappa n/a n/a
2 male 64 IgA kappa Stage II yes
3 male 54 IgA kappa Stage II no
4 female 56 IgA lambda Stage II n/a
5 male 59 kappa Stage I no
6 male 48 IgG kappa Stage I no
7 female 74 IgG lambda Stage II no
8 female 62 IgG kappa Stage I no
9 male 63 kappa Stage III yes
10 male 47 kappa Stage II no
11 male 59 IgG kappa Stage I no
12 male 72 IgG lambda Stage II no
13 male 61 kappa Stage II yes
14 male 68 IgG kappa Stage II yes
15 male 61 IgG kappa Stage I no
16 female 61 IgG kappa Stage II yes
17 male 37 kappa Stage I no
18 male 79 IgG kappa n/a no
19 male 68 kappa Stage II no
20 female 43 IgG lambda Stage I no
21 male 46 lambda Stage II yes
22 female 44 IgG kappa Stage II n/a
n/a = not available; high-risk cytogenetics is defined as t (4;14) and/or t (14;16) and/or del(17p); Ig: Immunoglobulin;
R-ISS = Revised International Staging System.
4.2. PET/CT Acquisition
18F-FDG and 11C-MET were synthesized in-house with a 16 MeV Cyclotron (Würzburg; GE
PET trace 6; GE Healthcare, Milwaukee, USA) or an 18 MeV Cyclotron (Navarra; Cyclone 18/9, IBA
Radiopharma Solutions, Belgium). PET/CT was performed in both institutions on a PET/CT scanner
(Siemens Biograph mCT 64, Siemens, Knoxville, USA) within a median interval of 1 day between
18F-FDG and 11C-MET scans (range, 0–11).
Patients fasted at least 4 hours before 18F-FDG (3 to 5 MBq/kg) and 11C-MET injection (6–10 MBq/kg).
No adverse effects associated to radiotracer injection were observed. PET/CT scans were acquired
after 60 min (8F-FDG) or 20 min (11C-MET), using contrast-enhanced CT with dose modulation and
a quality reference of 210 mAs (Würzburg)) or non-contrast-enhanced CT with Care Dose 4D and a
quality reference of 80–120 mAs (Würzburg, Navarra), including the skull to the proximal thighs and
lower limbs. Consecutively, PET emission data were acquired in 3D-mode with 2 min (Würzburg)
or 2–3 min (Navarra) emission time per bed position in the skull to mid-thighs and 1 min/bed in the
lower limbs. After decay and scatter correction, PET data were reconstructed according to standard
protocols consisting of 3D ordinary Poisson ordered-subset expectation maximization (OSEM) iterative
reconstruction with time-of-flight and point spread function modeling, 3 iterations, and 21 subsets,
a 2 mm full-width at half-maximum Gaussian post-filter and a 200 × 200 image matrix.
4.3. PET/CT Assessment
Two experienced nuclear medicine physicians (M.J.G.-V. and C.L.) blinded to the results of clinical
and biologic data visually assessed PET/CT anonymized images. 18F-FDG PET maximum intensity
projection (MIP) and axial/sagittal/coronal images were reviewed and focal lesions as well as bone
infiltration were characterized following the patterns defined by Moreau et al [7].
For 11C-MET, every focal uptake with higher activity than the surrounding normal tissue or
contralateral structure was considered positive. Criteria for the diagnosis of involvement of BM was
focally increased 11C-methionine uptake in the BM or diffusely increased 11C-methionine in the whole
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hematopoietic BM with or without the expansion of BM into distal parts of long bones [14]. BM biopsy,
performed without clinical information nor PET/CT results, served as the standard of reference in
all cases.
Thereafter, 18F-FDG and 11C-MET PET/CT images underwent a three-dimensional volume
of interest analysis of the axial and appendicular skeleton with “PET/CT Viewer Beth Israel for
FIJI” [25–27]. This software allows calculating SUVmax, SUVmean and SUVpeak values as well as the
new biomarkers MTV, which were defined for each lesion as the sum of voxels exceeding an absolute
SUV threshold or relative threshold, and the TLG, which was calculated with the following formula:
TLG =
∑
(SUVmean ×MTV). For 11C-MET PET, the equivalent term for TLG was the total lesion
methionine uptake (TLMU), which was defined as MTV times the mean standardized uptake values
(SUVmean) within the boundary [28]. The total MTV (TMTV) in each patient was defined as the sum
of MTV of all the individual lesions obtained.
For the calculation of tumor volume biomarkers, the software automatically delineated the
tumor volume, requiring operator supervision to discard those physiological uptakes (bladder, brain,
liver, etc.). Later, a threshold was set so that the software detected all voxels included in that cut-off point.
In addition to the 41% of SUVmax threshold (calculated at the local maximum point) recommended by
the European Association of Nuclear Medicine [29], other absolute (SUV > 1, 3, and 4) and relative
thresholds (SUV > 30% and 50% of SUVmax) were used to segment the images (Figure S1). Finally,
the automatically generated thresholds were evaluated, and the threshold that best fit with the visually
identified active lesions was chosen. In 18F-FDG PET/CT, the best threshold for segmentation was
SUV > 41% of SUVmax in 15/22 patients (68.2%), while in other patients, different thresholds were
eligible because of under- or overestimation. The second most selected threshold was SUV > 4 in
4/22 patients (18.2%), and the remaining cases corresponded to a threshold of SUV > 50% SUVmax
in 2/22 patients (9.1%) and SUV >1 in 1 patient (4.5%). An example of these different criteria is
demonstrated in Figure S1. In 11C-MET PET/CT, similar results were obtained, with a relative threshold
SUV > 41% SUVmax as the most frequently selected (16/22, 72.7%), and some cases with different
thresholds because of under- or overestimation, SUV > 30% SUVmax (1/22, 4.5%), SUV > 50% SUVmax
(1/22, 4.5%), and SUV > 4 (4/22, 18.2%). Overall, in 10 patients with focal disease in 18F-FDG, different
segmentation methods on FIJI software were employed and are shown in Table S2. Figure S2 shows a
representative image of the impaired results of selecting a fixed threshold of SUV > 41% SUVmax in
the case of focal disease. Interestingly, when a diffuse or combined focal/diffuse pattern was present,
only relative thresholds fit better with the disease extension in all cases. This pattern was also present
for 11C-MET PET/CT with the exception of two cases with combined infiltration in which SUV > 4
was preferred.
4.4. Statistical Analysis
Quantitative data are presented as the median, inter-quartile range (IQR), and mean ± SD,
as appropriate. Spearman correlation was used to estimate linear relationships. A Chi square or
Fisher exact test was conducted for comparison of frequency data between independent subgroups.
The Wilcoxon test was the non-parametric statistical test used to compare two related samples, matched
samples, or repeated measurements. A comparison of quantitative values from three independent
groups was performed using the Kruskal–Wallis test. Concordance between 11C-MET and 18F-FDG
PET imaging was presented in a two-way table. The level of agreement between the two evaluations
was expressed by kappa statistics. Correlations between categorical and quantitative variables were
performed using Spearman’s Rho.
Statistical analyses were performed in R (version 3.4.4, R Core Team, Vienna, Austria, 2018) and
SPSS (version 22.0; SPSS, Inc. Chicago, IL, USA). All statistical tests were performed two-sided, and a
p-value < 0.05 was considered to indicate statistical significance.
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5. Conclusions
In summary, our preliminary results show that 11C-MET seems to be a more sensitive and accurate
surrogate for total myeloma burden as compared to 18F-FDG. Our results might stimulate future
research and be considered as groundwork for future prospective studies with larger sample sizes.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/4/1042/s1,
Table S1: Patients’ characteristics, Table S2: Thresholds selected for FIJI software, Figure S1: Example of
different cut-off values performed for both tracers, Figure S2: Example of impaired results of a fixed threshold of
SUV > 41% SUVmax.
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